13 recruiting, 11 completed, 7 active not recruiting, 5 terminated. 40 Phase 2, 10 Phase 1, 3 Phase 3.
Follow alectinib: new trials by email Literature Review of alectinib trials Research Report on alectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Alectinib, Entrectinib, Surgery - Infant-Type Hemispheric Glioma | Phase 2 | Not yet recruiting | St. Jude Children's Research Hospital | 50 | 2026-11-01 | 2026-11-04 |
| Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Alectinib - Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | China Medical University Hospital | 10 | 2026-05-15 | 2026-05-11 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements Alectinib, Stereotactic Radiosurgery - Lung Cancer, NSCLC | Phase 1 / Phase 2 | Recruiting | Joshua Palmer | 56 | 2024-03-07 | 2026-04-08 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| Alectinib Pharmacokinetic in Patients With NSCLC Alectinib Oral Product - Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation | Phase 1 / Phase 2 | Recruiting | Instituto Nacional de Cancerologia de Mexico | 45 | 2022-05-01 | 2026-04-08 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma Crizotinib - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 90 | 2021-11-13 | 2024-09-20 |
| CRAFT: The NCT-PMO-1602 Phase II Trial Vemurafenib, Cobimetinib, Atezolizumab - Metastatic or Locally Advanced Malignancies | Phase 2 | Completed | German Cancer Research Center | 72 | 2021-10-13 | 2025-01-08 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors Alectinib - ALK Fusion-positive Solid or CNS Tumors | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 42 | 2021-09-14 | 2026-11-12 |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Alectinib - Neoplasms, Colorectal Neoplasms | Phase 2 | Terminated | Hoffmann-La Roche | 1 | 2021-05-24 | 2023-08-07 |
| Alectinib in Neo-adjuvant Treatment of Stage III NSCLC Alectinib - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 33 | 2021-05-20 | 2024-08-09 |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway Atezolizumab - Cancer Metastatic | Phase 2 | Recruiting | Oslo University Hospital | 3000 | 2021-04-01 | 2024-02-29 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Entrectinib, Alectinib, Atezolizumab - Solid Tumors | Phase 2 | Active not recruiting | Hoffmann-La Roche | 920 | 2021-01-18 | 2026-09-04 |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy | Phase 2 | Completed | Genentech, Inc. | 252 | 2021-01-13 | 2025-01-08 |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Alectinib, Entrectinib, Vemurafenib - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Genentech, Inc. | 99 | 2020-11-06 | 2026-11-10 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
Showing 20 of 40. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (17) · Neoplasms (6) · Brain Neoplasms (4) · Lung Neoplasms (4) · Hematologic Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms by Site (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Thyroid Neoplasms (2)
Hoffmann-La Roche (8) · Genentech, Inc. (3) · Cancer Research UK (2) · Hunan Province Tumor Hospital (2) · Instituto Nacional de Cancerologia de Mexico (2) · Massachusetts General Hospital (2) · Oslo University Hospital (2) · AstraZeneca (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Leon Berard (1) · China Medical University Hospital (1) · Dana-Farber Cancer Institute (1) · ETOP IBCSG Partners Foundation (1) · Fondazione per la Medicina Personalizzata (1) · German Cancer Research Center (1)
United States (16) · Italy (9) · France (7) · Spain (7) · United Kingdom (7) · China (6) · Denmark (6) · Germany (6) · South Korea (6) · Australia (5) · Brazil (5) · Netherlands (5) · Belgium (4) · Canada (4) · Japan (4)
Matthew Krebs, Dr (2) · Oscar G Arrieta Rodriguez, M.D., M.Sc. (2) · Yongchang Zhang, MD (2) · Aditi Bagchi, M.D., Ph.D. (1) · Andrea Botticelli (1) · Charles Swanton (1) · Diogo Gomes, MD (1) · E.E. Voest, prof. (1) · Egbert F. Smith, MD-PhD (1) · Enriqueta Felip, MD-PhD (1) · Helena A Yu, MD (1) · Ibiayi T Dagogo-Jack, MD (1)
PMID 27863201, PMID 29748847, PMID 31706099, PMID 41213248, PMID 22327623, PMID 23814043, PMID 25153538, PMID 25349307, PMID 26708155, PMID 27130468, PMID 27544060, PMID 28447912, PMID 29320312, PMID 30857956, PMID 32009824, PMID 32027845, PMID 34083331, PMID 34339623, PMID 34389237, PMID 34808524, PMID 34876409, PMID 35086719, PMID 35568909, PMID 35598186, PMID 35649212, PMID 35995953, PMID 36814246, PMID 36870947, PMID 37424386, PMID 37793085, PMID 38190582, PMID 38630551, PMID 38898120, PMID 39096924, PMID 39521433, PMID 40086048, PMID 40466026, PMID 40525978, PMID 40913172, PMID 41023484, PMID 41130408, PMID 41392942, PMID 41780641, PMID 41963505, PMID 41986720, PMID 42361644, PMID 42691436
2017 (3), 2023 (3), 2018 (2), 2015 (1), 2016 (1), 2019 (1), U10CA180868 (1)